Alkermes
potential indications in neurodegenerative and disorders with cognitive deficits indications that share common of synaptic dysfunction in hippocampus with deficits in cognition includes certain autism spectrum disorders with reduced synaptic density initial clinical focus on rare and orphan diseases with potential expedited development pathways plan to select lead indications based on preclinical and human data potential indications focused on rare and orphan diseases neurodegenerative disease dementia in down syndrome syndrome syndrome syndrome tuberous sclerosis complex pay by | Alkermes
Company
Deck Type
Deck date
March 2021
Slide
125 of 144
Related slides by other companies
Results
May 2021
IPO
September 2020
IPO
September 2020
IPO
September 2020
Other recent decks by Alkermes
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io